We recently published a list of Was Jim Cramer Right About These 13 Stocks? In this article, we are going to take a look at ...

We recently published a list of 8 Stocks in Focus Under Jim Cramer’s Game Plan. In this article, we are going to take a look ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years ... respectively) from its drug shortage list, the agency is cutting off the primary legal route that allows ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.